Patent classifications
C07D275/04
KRAS G12C inhibitors and methods of using the same
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
ARYL ETHER COMPOUNDS AS TEAD MODULATORS
The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.
##STR00001##
Histone deacetylase inhibitors and compositions and methods of use thereof
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##
Histone deacetylase inhibitors and compositions and methods of use thereof
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##
MIF MODULATORS
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
MIF MODULATORS
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
MAGNETIC PARTICLE DISPERSION
The present invention relates to a magnetic particle dispersion, and the magnetic particle dispersion includes a magnetic particle, an isothiazoline compound, and an aqueous medium.
MAGNETIC PARTICLE DISPERSION
The present invention relates to a magnetic particle dispersion, and the magnetic particle dispersion includes a magnetic particle, an isothiazoline compound, and an aqueous medium.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.